Jefferies Boosts PT on Celldex Therapeutics (CLDX) to $15
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Celldex Therapeutics (CLDX) Posts Mixed Q4 Results
March 7, 2013 8:06 AM ESTCelldex Therapeutics (NASDAQ: CLDX) reported Q4 EPS of ($0.27), $0.02 worse than the analyst estimate of ($0.25). Revenue for the quarter came in at $3.65 million versus the consensus estimate of $2.45 million.
For earnings history and earnings-related data on Celldex Therapeutics (CLDX) click here.... More
